Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma-Reference-Cited by-同舟云学术

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Published:2017-02-17 Issue:6 Volume:31 Page:1446-1449
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Martinez-Lopez J,Sanchez-Vega B,Barrio S,Cuenca I,Ruiz-Heredia Y,Alonso R,Rapado I,Marin C,Cedena M-T,Paiva B,Puig N,Mateos M-V,Ayala R,Hernández M-T,Jimenez C,Rosiñol L,Martínez R,Teruel A-I,Gutiérrez N,Martin-Ramos M-L,Oriol A,Bargay J,Bladé J,San-Miguel J,Garcia-Sanz R,Lahuerta J-J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201758.pdf

Reference15 articles.

1. Martinez-Lopez J, Blade J, Mateos M-V, Grande C, Alegre A, García-Laraña J et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011; 118: 529–534.

2. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117: 3025–3031.

3. Paiva B, Gutiérrez NC, Rosiñol L, Vídriales M-B, Montalbán M-Á, Martínez-López J et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687–691.

4. Martínez-López J, Paiva B, López-Anglada L, Mateos M-V, Cedena T, Vidríales M-B et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood 2015; 126: 858–862.

5. Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015; 12: 286–295.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms;The Journal of Molecular Diagnostics;2023-12

2. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future;Cancers;2023-07-20

3. Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing;Experimental Hematology;2023-03

4. Looking for a needle in the haystack of CLL;Blood;2023-02-02

5. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma;Cancers;2023-01-15